CasNo.850649-62-6,Manufacture Raw Material CAS 850649-62-6 Alogliptin Benzoate,Alogliptin benzoate(850649-62-6) Suppliers

0	Negotiable

Min.Order :0
Purity: 99%

Keywords

Alogliptin benzoate Alogliptin Benzoate Raw Material 850649-62-6

Quick Details

Appearance:White to off-white powder
Application:Antidiabetics (DPP4 Inhibitor)
PackAge:Aluminum foil bag,fluorinated bottles,carboard drums or as your special request.
ProductionCapacity:
Storage:Store in cool & dry place. Keep away from strong light Shelf Life2 years when properly stored.
Transportation:1) Door to Door Service by DHL/FEDEX/EMS/TNT for package under 45kgs, about 3~7 days delivery. 2) Port to Port Service by Air for package more than 45kgs, about 3~7 days delivery. 3) Port to Port...

Superiority:

1) Provide costomers with "one-stop"packaging service,from research,development,production,export and so on.
2) We have our own R&D and production base,equipped with advanced production equipment and precision testing the Unitef States Pharmacopoeia(USP),the Britis Pharmacopoeia(EP) and other international advanced standards.All products are through the KOSGER,HALAL certification,the ISO quality management system certification and the HACCP certification.
3) More than 12 years of export experience.
4)Competitive price in China market.

Details:

Alogliptin benzoate is a serine protease two peptide peptidase IV (DPP- IV) inhibitor developed by Takeda company in japan. This product can maintain the levels of glucagon like peptide 1 (GLP-1) and Glucose dependent insulin-like growth polypeptide (GIP) in vivo and promote the secretion of insulin and thus exert hypoglycemic effect. A randomized, placebo-controlled clinical trial results showed that, compared with placebo Agger gliptin monotherapy can significantly improve glycemic control in type 2 diabetes, did not increase the incidence of hypoglycemia, well tolerated. A Glenn Dean and the medicine composition is the sitagliptin, vildagliptin asked the city after oral administration of effective specific DPP- IV inhibitors, provides a new choice of treatment for patients with type 2 diabetes, and has wide application prospect.